Microbioreactors are a convenient research tool, enabling cost-effective screening of a variety of fermentation parameters prior to scale-up and manufacturing of biological products. m2p-labs’ proprietary bioreactor technology offers automated, parallel monitoring of multiple micro-fermentations, and has been proven in applications such as clone screening, media optimization and synthetic biology.
The biosimilars market is expanding rapidly as the patents expire for an increasing number of high profile biopharmaceutical agents. The complex nature of biologics requires extensive characterization of the production techniques and in vivo effects of new biosimilars before they can be released onto the market. Coherus Biosciences is using advanced laboratory automation to help screen chromatography conditions as part of its downstream purification processes for new biosimilars.
UCL’s Advanced Centre for Biochemical Engineering is harnessing the flexible automation capabilities of its Freedom EVO® workstations to explore novel bioprocessing applications, with a focus on the production of ‘next generation’ medicines including protein-derived therapeutics, vaccines and cells for therapy.
Extended periods of walkaway operation are essential to the work carried out by Spanish energy producer Repsol, which relies on two Freedom EVO® platforms and Tecan’s 350 μl nested liquid handling disposable tips for its research into alternative energy sources.
The Institut Européen de Chimie et Biologie is investigating a variety of innovative aptamer-based applications, and depends on two Freedom EVO® platforms for reliable automation of its selection and production processes.
Global biopharma company UCB has increased the throughput of its antibody purification pipeline, using a flexible Freedom EVO® workstation to miniaturize its chromatography applications. As a result, the Company is able to investigate far more parameters in a fraction of the time, while consuming significantly less material.